MedTrace Logo

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

NCT06299436 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-12

No results posted yet for this study

Summary

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Pulmonary Hypertension
  • Right Heart Failure Due to Left Heart Failure

Sponsors & Collaborators

Principal Investigators

  • Steven Hsu, MD · Johns Hopkins School of Medicine

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06299436 on ClinicalTrials.gov